$AMRN Now, I know all of you have put the mineral oil issue to bed. And well you should! FDA agreed with Amarin and all the 3-letter KOL’s that it wasn’t an issue at least to the extent of compromising those outstanding stat-sig results of REDUCE-IT. But I have unrelentingly stated that TRILOGY results will either confirm the consensus opinion or turn over the apple cart. I’ve already quoted Acasti’s CEO who unequivocally stated that mineral oil attenuates statin performance in her last quarterly call on November 13th. Thanks to @MooseG stocktwits.com/MooseG/messa... we now know that 50% of TRILOGY’s 250 control patients or roughly 125 will be on stains. Each study will, therefore have approximately 62 patients to evaluate over the 12-26 week periods when statin parameters in control rose most steeply in all 3 Amarin studies. I put this to you plainly. If those same parameters fall in TRILOGY the sh*t will hit the proverbial fan. Just watch!